Surveillance Frequency Doesn't Cut Mortality in Colorectal Cancer

Share this content:
Surveillance Frequency Doesn't Cut Mortality in Colorectal Cancer
Surveillance Frequency Doesn't Cut Mortality in Colorectal Cancer

TUESDAY, May 22, 2018 (HealthDay News) -- For patients with colorectal cancer after curative surgery, the frequency of surveillance is not associated with mortality; and, the intensity of posttreatment surveillance is not associated with detection of recurrence, according to two studies published in the May 22/29 issue of the Journal of the American Medical Association.

Peer Wille-Jørgensen, D.M.Sc., from Bispebjerg Hospital in Copenhagen, Denmark, and colleagues randomized 2,509 patients with stage II or III colorectal cancer after curative surgery to follow-up testing with computed tomography of the thorax and abdomen and serum carcinoembryonic antigen (CEA) at high frequency (1,253 patients) or low frequency (1,256 patients). The researchers found that the five-year overall patient mortality rate was 13.0 and 14.1 percent in the high- and low-frequency groups, respectively (risk difference, 1.1 percent; 95 percent confidence interval, −1.6 to 3.8 percent; P = 0.43).

Rebecca A. Snyder, M.D., M.P.H., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues abstracted data from the medical records of 8,529 patients diagnosed with stage I, II, or III CRC in 2006 to 2007 with follow-up through Dec. 31, 2014. For patients treated at facilities with high-intensity and low-intensity imaging surveillance, the median time to detection of recurrence was 15.1 and 16.0 months, respectively (difference, −0.95 months; 95 percent confidence interval, −2.59 to 0.68 months). The median time to recurrence was 15.9 and 15.3 months for those treated at facilities with high- versus low-intensity CEA testing, respectively (difference, 0.59 months; 95 percent confidence interval, −1.33 to 2.51).

"Among patients treated for stage I, II, or III CRC, there was no significant association between surveillance intensity and detection of recurrence," Snyder and colleagues write.

One author from each study disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text - Wille-Jørgensen
Abstract/Full Text - Snyder
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »